242 related articles for article (PubMed ID: 20442302)
1. mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities.
Liu H; D'Andrade P; Fulmer-Smentek S; Lorenzi P; Kohn KW; Weinstein JN; Pommier Y; Reinhold WC
Mol Cancer Ther; 2010 May; 9(5):1080-91. PubMed ID: 20442302
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA expression profiles for the NCI-60 cancer cell panel.
Blower PE; Verducci JS; Lin S; Zhou J; Chung JH; Dai Z; Liu CG; Reinhold W; Lorenzi PL; Kaldjian EP; Croce CM; Weinstein JN; Sadee W
Mol Cancer Ther; 2007 May; 6(5):1483-91. PubMed ID: 17483436
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons.
Gmeiner WH; Reinhold WC; Pommier Y
Mol Cancer Ther; 2010 Dec; 9(12):3105-14. PubMed ID: 21159603
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.
Holbeck SL; Collins JM; Doroshow JH
Mol Cancer Ther; 2010 May; 9(5):1451-60. PubMed ID: 20442306
[TBL] [Abstract][Full Text] [Related]
5. RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.
Reinhold WC; Varma S; Sunshine M; Elloumi F; Ofori-Atta K; Lee S; Trepel JB; Meltzer PS; Doroshow JH; Pommier Y
Cancer Res; 2019 Jul; 79(13):3514-3524. PubMed ID: 31113817
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
[TBL] [Abstract][Full Text] [Related]
7. The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.
Monks A; Zhao Y; Hose C; Hamed H; Krushkal J; Fang J; Sonkin D; Palmisano A; Polley EC; Fogli LK; Konaté MM; Miller SB; Simpson MA; Voth AR; Li MC; Harris E; Wu X; Connelly JW; Rapisarda A; Teicher BA; Simon R; Doroshow JH
Cancer Res; 2018 Dec; 78(24):6807-6817. PubMed ID: 30355619
[TBL] [Abstract][Full Text] [Related]
8. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study.
Shankavaram UT; Reinhold WC; Nishizuka S; Major S; Morita D; Chary KK; Reimers MA; Scherf U; Kahn A; Dolginow D; Cossman J; Kaldjian EP; Scudiero DA; Petricoin E; Liotta L; Lee JK; Weinstein JN
Mol Cancer Ther; 2007 Mar; 6(3):820-32. PubMed ID: 17339364
[TBL] [Abstract][Full Text] [Related]
9. Global microRNA analysis of the NCI-60 cancer cell panel.
Søkilde R; Kaczkowski B; Podolska A; Cirera S; Gorodkin J; Møller S; Litman T
Mol Cancer Ther; 2011 Mar; 10(3):375-84. PubMed ID: 21252286
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
11. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
12. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.
Reinhold WC; Sunshine M; Liu H; Varma S; Kohn KW; Morris J; Doroshow J; Pommier Y
Cancer Res; 2012 Jul; 72(14):3499-511. PubMed ID: 22802077
[TBL] [Abstract][Full Text] [Related]
13. Expression of microRNAs in the NCI-60 cancer cell-lines.
Patnaik SK; Dahlgaard J; Mazin W; Kannisto E; Jensen T; Knudsen S; Yendamuri S
PLoS One; 2012; 7(11):e49918. PubMed ID: 23209617
[TBL] [Abstract][Full Text] [Related]
14. Identification of reciprocal microRNA-mRNA pairs associated with metastatic potential disparities in human prostate cancer cells and signaling pathway analysis.
Ma H; Wang LY; Yang RH; Zhou Y; Zhou P; Kong L
J Cell Biochem; 2019 Oct; 120(10):17779-17790. PubMed ID: 31127646
[TBL] [Abstract][Full Text] [Related]
15. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
Okabe M; Szakács G; Reimers MA; Suzuki T; Hall MD; Abe T; Weinstein JN; Gottesman MM
Mol Cancer Ther; 2008 Sep; 7(9):3081-91. PubMed ID: 18790787
[TBL] [Abstract][Full Text] [Related]
16. Sho-saiko-to, a traditional herbal medicine, regulates gene expression and biological function by way of microRNAs in primary mouse hepatocytes.
Song KH; Kim YH; Kim BY
BMC Complement Altern Med; 2014 Jan; 14():14. PubMed ID: 24410935
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the NCI-60 dataset for cancer-related microRNA and mRNA using expression profiles.
Weng CW; Lee SC; Lee YL; Ng KL
Comput Biol Chem; 2013 Jun; 44():15-21. PubMed ID: 23499870
[TBL] [Abstract][Full Text] [Related]
18. Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.
Reinhold WC; Sunshine M; Varma S; Doroshow JH; Pommier Y
Clin Cancer Res; 2015 Sep; 21(17):3841-52. PubMed ID: 26048278
[TBL] [Abstract][Full Text] [Related]
19. Correlation of expression profiles between microRNAs and mRNA targets using NCI-60 data.
Wang YP; Li KB
BMC Genomics; 2009 May; 10():218. PubMed ID: 19435500
[TBL] [Abstract][Full Text] [Related]
20. mRNA and microRNA expression profiles of radioresistant NCI-H520 non-small cell lung cancer cells.
Guo W; Xie L; Zhao L; Zhao Y
Mol Med Rep; 2015 Aug; 12(2):1857-67. PubMed ID: 25873351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
